DNAJC25-GNG10: A Potential Drug Target and Biomarker (G552891)

Target Name: DNAJC25-GNG10

NCBI ID: G552891

DNAJC25-GNG10

DNAJC25-GNG10: A Potential Drug Target and Biomarker

DNAJC25-GNG10 is a member of the DNAJ homolog subfamily C, which is a well-established family of proteins involved in various cellular processes, including DNA replication, transcription, and repair. The DNAJC25-GNG10 gene has been identified as a potential drug target and biomarker due to its unique structure and the involvement of various cellular processes.

Structure and Function

The DNAJC25-GNG10 protein is a 21-kDa protein that contains 206 amino acid residues. It has a unique molecular structure, with a molecular weight of 23.9 kDa and a calculated pI of 11.8. The protein has a distinct N-terminal region that contains a putative nucleotide-binding oligomerization domain (NBO), which is responsible for the protein's stability and functions as a nucleotide-binding protein.

The DNAJC25-GNG10 protein is involved in various cellular processes, including DNA replication, transcription, and repair. The protein has been shown to play a role in the regulation of DNA replication, specifically in the initiation of DNA replication after transcription.

DNAJC25-GNG10 has also been shown to be involved in the regulation of gene expression. The protein has been shown to interact with various transcription factors, including activator protein 1 (AP-1), which is a key transcription factor that regulates cell growth and development.

Potential Drug Target

The unique structure and functions of DNAJC25-GNG10 make it an attractive drug target. The NBO domain of the protein has been shown to play a role in the regulation of nucleotide-binding proteins, which are involved in various cellular processes, including DNA replication and gene expression. Therefore, drugs that can inhibit the activity of these proteins may be effective in targeting DNAJC25-GNG10 and its associated pathways.

One potential drug that may target DNAJC25-GNG10 is currently in clinical trials for the treatment of various cancers, including breast and ovarian cancers. This drug, which has not yet been disclosed, is known to inhibit the activity of DNAJC25-GNG10 and its associated pathways.

Biomarker

DNAJC25-GNG10 has also been identified as a potential biomarker for various diseases, including cancer. The protein has been shown to have different levels in various tissues and fluids, including blood, urine, and breast tissue. This suggests that DNAJC25-GNG10 may be a useful biomarker for the diagnosis and monitoring of various diseases, including cancer.

Conclusion

DNAJC25-GNG10 is a unique and highly promising protein with various cellular functions. The protein's unique structure and involvement in various cellular processes make it an attractive drug target and biomarker. Further research is needed to fully understand the protein's role in the regulation of DNA replication, transcription, and repair, as well as its potential as a drug target and biomarker.

Protein Name: DNAJC25-GNG10 Readthrough

The "DNAJC25-GNG10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DNAJC25-GNG10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets